# PYRUKYND® (pyrukynd) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pyrukynd

> The FDA approved PYRUKYND® (pyrukynd), sponsored by AGIOS PHARMACEUTICALS, INC. (AGIO), on Feb 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | PYRUKYND® (pyrukynd) |
| Codes |  |
| Sponsor | AGIOS PHARMACEUTICALS, INC. (AGIO) https://sec-api.dev/companies/agio/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Feb 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-13, last confirmed 2025-02-13.
- SEC Form 10-K (accession 0001439222-25-000009): "Total Revenue - 2023 vs. 2022 - The increase in total revenue of $12.6 million in 2023 compared to 2022 was due to increased product revenue associated with PYRUKYND®, which was approved by the FDA in February 2022, partially offset by revenue recognized in 2022 associated with the licensing of intellectual property for our Friedreich's Ataxia preclinical program." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm

### Dec 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-10-30, last confirmed 2025-10-30.
- SEC Form 10-Q (accession 0001439222-25-000116): "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm
- SEC Form 10-Q (accession 0001439222-25-000116): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm

### Dec 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-02-13, last confirmed 2025-07-31.
- SEC Form 10-Q (accession 0001439222-25-000089): "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000089/agio-20250630.htm
- SEC Form 10-Q (accession 0001439222-25-000089): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000089/agio-20250630.htm
- SEC Form 10-Q (accession 0001439222-25-000089): "In December 2024, we announced that we submitted an sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000089/agio-20250630.htm
- SEC Form 10-Q (accession 0001439222-25-000036): "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000036/agio-20250331.htm
- SEC Form 10-Q (accession 0001439222-25-000036): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000036/agio-20250331.htm
- SEC Form 10-Q (accession 0001439222-25-000036): "In December 2024, we announced that we submitted an sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000036/agio-20250331.htm
- SEC Form 10-Q (accession 0001439222-25-000036): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000036/agio-20250331.htm
- SEC Form 10-K (accession 0001439222-25-000009): "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm
- SEC Form 10-K (accession 0001439222-25-000009): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm
- SEC Form 10-K (accession 0001439222-25-000009): "In December 2024, we announced that we submitted an sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm
- SEC Form 10-K (accession 0001439222-25-000009): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-01-13, last confirmed 2025-07-31.
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000087): ""In the second quarter, we made progress advancing our early- and mid-stage pipeline and remain on track to deliver topline results of the RISE UP Phase 3 trial for PYRUKYND in sickle cell disease by the end of the year." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004943): "PYRUKYND® in Sickle Cell Disease with Expected Readout in Late 2025 Abbreviations: BID = twice daily; Hb = hemoglobin; SCPC = sickle cell pain crises; HU = hydroxyurea (1) Phase 2 and phase 3 components are part of a single study/protocol; (2)" https://www.sec.gov/Archives/edgar/data/1439222/000119312525004943/d131665dex992.htm

### September 7, 2025: PDUFA date

- Status: delayed. Date confidence: exact. Indication: Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia.
- First seen 2025-01-13, last confirmed 2025-07-31.
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000087): "•PYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025" https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000034): "•Thalassemia: Receive FDA regulatory decision for PYRUKYND for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia (PDUFA goal date is September 7, 2025)." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-050125xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000007): "•Thalassemia: Receive FDA regulatory decision for PYRUKYND for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia (PDUFA goal date is September 7, 2025)." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000007/agio-021325xfyxex991earnin.htm
- SEC Form 10-Q (accession 0001439222-25-000089): "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000089/agio-20250630.htm
- SEC Form 10-Q (accession 0001439222-25-000089): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000089/agio-20250630.htm
- SEC Form 10-Q (accession 0001439222-25-000089): "In December 2024, we announced that we submitted an sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000089/agio-20250630.htm
- SEC Form 10-Q (accession 0001439222-25-000036): "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000036/agio-20250331.htm
- SEC Form 10-Q (accession 0001439222-25-000036): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000036/agio-20250331.htm
- SEC Form 10-Q (accession 0001439222-25-000036): "In December 2024, we announced that we submitted an sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000036/agio-20250331.htm
- SEC Form 10-Q (accession 0001439222-25-000036): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000036/agio-20250331.htm
- SEC Form 10-K (accession 0001439222-25-000009): "In December 2024, we announced that we submitted a supplemental new drug application, or sNDA, to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm
- SEC Form 10-K (accession 0001439222-25-000009): "In December 2024, we announced that we submitted an sNDA to the FDA for PYRUKYND® for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, which was accepted with standard review by the FDA and granted a PDUFA goal date of September 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm

### September 7, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-10-30, last confirmed 2025-10-30.
- SEC Form 10-Q (accession 0001439222-25-000116): "The FDA accepted the sNDA and granted a PDUFA goal date of September 7, 2025, which the FDA subsequently extended to December 7, 2025 following our submission of a proposed REMS to mitigate the risk of hepatocellular injury that was described in the original PYRUKYND® sNDA." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm
- SEC Form 10-Q (accession 0001439222-25-000116): "The FDA accepted the sNDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025, which the FDA subsequently extended to December 7, 2025 following our submission of a proposed Risk Evaluation and Mitigation Strategy, or REMS, to mitigate the risk of hepatocellular injury that was described in the original sNDA filing." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm

### December 7, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-10-30, last confirmed 2025-10-30.
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000114): "•PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025" https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-103125xfyxex991earnin.htm
- Press release filed with the SEC (EX-99) (accession 0001439222-25-000114): "▪U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia by three months, to December 7, 2025." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-103125xfyxex991earnin.htm
- SEC Form 10-Q (accession 0001439222-25-000116): "The FDA accepted the sNDA and granted a PDUFA goal date of September 7, 2025, which the FDA subsequently extended to December 7, 2025 following our submission of a proposed REMS to mitigate the risk of hepatocellular injury that was described in the original PYRUKYND® sNDA." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm
- SEC Form 10-Q (accession 0001439222-25-000116): "The FDA accepted the sNDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of September 7, 2025, which the FDA subsequently extended to December 7, 2025 following our submission of a proposed Risk Evaluation and Mitigation Strategy, or REMS, to mitigate the risk of hepatocellular injury that was described in the original sNDA filing." https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm

Calendar months: [September 2025](https://sec-api.dev/fda-calendar/2025-09), [December 2025](https://sec-api.dev/fda-calendar/2025-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pyrukynd.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PYRUKYND® (pyrukynd) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pyrukynd

```bibtex
@misc{secapidev_pdufa_pyrukynd_20261116,
  title        = {PYRUKYND® (pyrukynd) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pyrukynd}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pyrukynd_20261116","title":"PYRUKYND® (pyrukynd) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pyrukynd","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
